Francine Hébert

741 total citations
18 papers, 632 citations indexed

About

Francine Hébert is a scholar working on Epidemiology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Francine Hébert has authored 18 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 7 papers in Oncology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Francine Hébert's work include Neuroendocrine Tumor Research Advances (7 papers), Lung Cancer Research Studies (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Francine Hébert is often cited by papers focused on Neuroendocrine Tumor Research Advances (7 papers), Lung Cancer Research Studies (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Francine Hébert collaborates with scholars based in United States and Canada. Francine Hébert's co-authors include Andrew V. Schally, Kate Groot, Károly Szepesházi, Gábor Halmos, Jean‐Claude Fouron, Attila Nagy, Patricia Armatis, József L. Varga, Baodong Sun and Hippokratis Kiaris and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Clinical Endocrinology & Metabolism and Endocrinology.

In The Last Decade

Francine Hébert

18 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francine Hébert United States 15 251 247 240 185 118 18 632
R. Yoshiyuki Osamura Japan 16 196 0.8× 171 0.7× 248 1.0× 201 1.1× 131 1.1× 39 779
Hicham Lahlou France 13 263 1.0× 204 0.8× 101 0.4× 335 1.8× 40 0.3× 14 843
Alejandro Ibáñez‐Costa Spain 18 112 0.4× 299 1.2× 391 1.6× 312 1.7× 77 0.7× 49 902
J. Hansson Sweden 10 127 0.5× 171 0.7× 42 0.2× 168 0.9× 176 1.5× 13 574
Kiyoshi Shingū Japan 14 193 0.8× 71 0.3× 168 0.7× 190 1.0× 48 0.4× 34 572
Hajime Kanauchi Japan 12 220 0.9× 83 0.3× 128 0.5× 200 1.1× 56 0.5× 25 529
J. P. Moreau France 11 171 0.7× 609 2.5× 569 2.4× 267 1.4× 26 0.2× 16 1.0k
M J Delisle France 10 123 0.5× 64 0.3× 506 2.1× 156 0.8× 35 0.3× 20 750
Florian Ehehalt Germany 16 363 1.4× 234 0.9× 142 0.6× 265 1.4× 51 0.4× 26 837
Miyuki Katai Japan 13 113 0.5× 174 0.7× 71 0.3× 206 1.1× 35 0.3× 35 576

Countries citing papers authored by Francine Hébert

Since Specialization
Citations

This map shows the geographic impact of Francine Hébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francine Hébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francine Hébert more than expected).

Fields of papers citing papers by Francine Hébert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francine Hébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francine Hébert. The network helps show where Francine Hébert may publish in the future.

Co-authorship network of co-authors of Francine Hébert

This figure shows the co-authorship network connecting the top 25 collaborators of Francine Hébert. A scholar is included among the top collaborators of Francine Hébert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francine Hébert. Francine Hébert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Koochekpour, Shahriar, Grace A. Maresh, Adrienne Katner, et al.. (2004). Establishment and characterization of a primary androgen‐responsive African‐American prostate cancer cell line, E006AA. The Prostate. 60(2). 141–152. 52 indexed citations
2.
Koochekpour, Shahriar, et al.. (2004). 580: Prosaposin is a Novel AR-Target Gene and Upregulates AR/PSA Expression in Prostate Stromal and Cancer Cells. The Journal of Urology. 171(4S). 154–154. 1 indexed citations
3.
Schally, Andrew V., József L. Varga, Célia A. Kanashiro, et al.. (2003). Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.. PubMed. 63(22). 7913–9. 50 indexed citations
4.
Schally, Andrew V., Károly Szepesházi, Ana M. Bajo, et al.. (2003). Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. International Journal of Oncology. 22(5). 1141–6. 14 indexed citations
5.
6.
Bajo, Ana M., Andrew V. Schally, Magdalena Krupa, et al.. (2002). Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c- jun and c- fos oncogenes. Proceedings of the National Academy of Sciences. 99(6). 3836–3841. 36 indexed citations
7.
Szepesházi, Károly, Andrew V. Schally, Gábor Halmos, et al.. (2002). Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.. PubMed. 62(3). 781–8. 40 indexed citations
8.
Kiaris, Hippokratis, Andrew V. Schally, Attila Nagy, et al.. (2001). A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. European Journal of Cancer. 37(5). 620–628. 42 indexed citations
9.
Szepesházi, Károly, Andrew V. Schally, Patricia Armatis, et al.. (2001). Antagonists of GHRH Decrease Production of GH and IGF-I in MXT Mouse Mammary Cancers and Inhibit Tumor Growth. Endocrinology. 142(10). 4371–4378. 36 indexed citations
10.
Szepesházi, Károly, Andrew V. Schally, Gábor Halmos, et al.. (2001). Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.. PubMed. 7(9). 2854–61. 34 indexed citations
11.
Chatzistamou, Ioulia, Andrew V. Schally, Károly Szepesházi, et al.. (2001). Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Letters. 171(1). 37–45. 25 indexed citations
12.
Szepesházi, Károly, Andrew V. Schally, Kate Groot, et al.. (2000). Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. European Journal of Cancer. 36(1). 128–136. 55 indexed citations
13.
Sun, Baodong, et al.. (2000). RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors. The Journal of Clinical Endocrinology & Metabolism. 85(10). 3509–3512. 31 indexed citations
14.
Płonowski, Artur, Andrew V. Schally, Attila Nagy, et al.. (2000). Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.. PubMed. 60(11). 2996–3001. 37 indexed citations
15.
16.
17.
Fouron, Jean‐Claude & Francine Hébert. (1973). The circulatory effects of hematocrit variations in normovolemic newborn lambs. The Journal of Pediatrics. 82(6). 995–1003. 42 indexed citations
18.
Fouron, Jean‐Claude & Francine Hébert. (1970). Cardiovascular adaptation of newborn lambs to hypervolemia with polycythemia. Canadian Journal of Physiology and Pharmacology. 48(5). 312–320. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Yoshiyuki Osamura Breakdown of academic impact, for papers by Hicham Lahlou Breakdown of academic impact, for papers by Alejandro Ibáñez‐Costa Breakdown of academic impact, for papers by J. Hansson Breakdown of academic impact, for papers by Kiyoshi Shingū Breakdown of academic impact, for papers by Hajime Kanauchi Breakdown of academic impact, for papers by J. P. Moreau Breakdown of academic impact, for papers by M J Delisle Breakdown of academic impact, for papers by Florian Ehehalt Breakdown of academic impact, for papers by Miyuki Katai
Rankless by CCL
2026